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Abstracts 
NO-40. OPTIC NEUROPATHY IN GLIOMA PATIENTS AFTER 
RECEIVING RADIOTHERAPY AND BEVACIZUMAB: RISK 
FACTORS AND RELATED QUALITY OF LIFE ISSUES 
Beverly Dan Fu and Daniela A. Bota; UC Irvine Medical Center, Orange, CA 
Focal beam radiation in combination with temozolomide is the standard 
treatment for malignant gliomas as well as nonresectable, high-risk WHO 
grade II gliomas. Bevacizumab treatment at time of recurrence is stipulated 
to increase the patient's survival. However, optic nerve neuropathy is one 
of the serious complications of radiotherapy, and there are very few articles 
that discuss the relationships between bevacizumab and optic nerve neuropa­
thy in the patients who develop bilateral optic nerve neuropathy during or 
after their treatment. The purpose of this study is to identify cases of bilateral 
optic nerve neuropathy in patients that received focal radiation and bevaci­
zumab and to delineate possible risk factors and related quality of life 
issues. The data collection protocol is approved by Institutional Research 
Board at University of California, Irvine. Two patients with bilateral optic 
neuropathy after receiving focal beam radiation and bevacizumab were 
identified. Both patients were started on bevacizurnab due to their tumor pro­
gression 2 months after completing radiation therapy, and the median time 
from the end of radiation to the onset of visual decline was 10.5 months. 
Case #1 is a 70-year-old Hispanic man with a nonresectable, bifrontal 
LGO who developed bilateral optic nerve neuropathy 7 months after starting 
on bevacizumab. Case #2 is an 82-year-old Asian man with the diagnosis of 
left frontal lobe GBM who developed bilateral optic nerve neuropathy 13 
months after the initiation of bevacizumab. Their mean radiation dose to 
the optic chiasm was 49.64 Gy. Focal beam radiation, as well as bevacizu­
mab, plays an important role in the treatment of gliomas. However, it is 
imperative for patients with the diagnosis of frontal tumors who were 
started on bevacizurnab shortly after radiation to have routine follow-up 
with neuro-ophthalmologist consultation, home health safety evaluation, 
clinical social worker involvement, and periodical MRI of the orbits if 
their symptoms warrants. 
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